Should I buy or sell Lineage Cell Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LCTX shares. View LCTX analyst ratings or view top-rated stocks .

What is Lineage Cell Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price objectives for Lineage Cell Therapeutics' shares. Their LCTX share price targets range from $6.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 403.9% from the stock's current price. View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts .

When is Lineage Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LCTX earnings forecast .

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04. The company earned $2.09 million during the quarter, compared to analyst estimates of $4.74 million. Lineage Cell Therapeutics had a negative net margin of 240.20% and a negative trailing twelve-month return on equity of 31.95%.

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB) , Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , ADMA Biologics (ADMA) , Novan (NOVN) , Pennsylvania Real Estate Investment Trust (PEI) , CNBX Pharmaceuticals (CNBX) , Enerplus (ERF) , KushCo (KSHB) and Zosano Pharma (ZSAN) .

Who are Lineage Cell Therapeutics' major shareholders?

Lineage Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fifth Third Wealth Advisors LLC (0.01%). Insiders that own company stock include Angus C Russell, Brian M Culley, Broadwood Partners, LP, Dipti Amin, Don M Bailey, Gary S Hogge and Michael H Mulroy. View institutional ownership trends .

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:LCTX

Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Free LCTX Stock Alerts

$1.29

+0.14 (+12.17%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.16
▼
$1.32
50-Day Range: N/A
52-Week Range: $0.84
▼
$1.61

Volume: 2.31 million shs
Average Volume: 957,170 shs
Market Capitalization: $243.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.50

Stock Analysis Analyst Forecasts Chart Earnings Headlines Insider Trades Ownership Short Interest

Get Lineage Cell Therapeutics alerts:

Lineage Cell Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 403.9% Upside
$6.50 Price Target
Short Interest: Bearish
5.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$7.10 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.13) to ($0.12) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Lineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
5.52% of the outstanding shares of Lineage Cell Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Lineage Cell Therapeutics has recently increased by 4.21%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Lineage Cell Therapeutics does not currently pay a dividend.
Dividend Growth
Lineage Cell Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LCTX.

1.1

News and Social Media Coverage

Search Interest
16 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
3 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lineage Cell Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,100,002.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
28.10% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lineage Cell Therapeutics is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lineage Cell Therapeutics is -9.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lineage Cell Therapeutics has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

LCTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LCTX Stock News Headlines

April 1, 2024 | finance.yahoo.com

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

March 28, 2024 | msn.com

5 Simple Wealth-Building Tips For This Generation's Forward-Thinkers

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

March 19, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release

March 18, 2024 | seekingalpha.com

Puma Biotechnology dips after dismissal of its suit was granted by a federal judge

March 18, 2024 | finance.yahoo.com

15 Best Anti-Aging Foods for Youthful Skin

March 18, 2024 | finance.yahoo.com

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

March 18, 2024 | businesswire.com

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

April 18, 2024 | Market Moving Trends (Ad)

Top 5 AI Stocks to Buy for 2024

March 14, 2024 | finance.yahoo.com

Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks

March 13, 2024 | finance.yahoo.com

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

March 11, 2024 | finance.yahoo.com

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy Advancements

March 8, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic Partnerships

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy Results

March 8, 2024 | insidermonkey.com

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript

March 7, 2024 | msn.com

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 7, 2024 | finance.yahoo.com

Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results

March 7, 2024 | benzinga.com

Lineage Cell Therapeutics: Q4 Earnings Insights

March 7, 2024 | businesswire.com

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 6, 2024 | benzinga.com

A Preview Of Lineage Cell Therapeutics's Earnings

February 29, 2024 | finance.yahoo.com

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

February 14, 2024 | benzinga.com

Lineage Cell Therapeutics Stock (AMEX:LCTX), Analyst Ratings, Price Targets, Predictions

February 13, 2024 | markets.businessinsider.com

Strong Buy Rating for Lineage Therap Backed by Promising Developments in Spinal Cord Injury Therapy

February 9, 2024 | finance.yahoo.com

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

February 9, 2024 | businesswire.com

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

February 7, 2024 | msn.com

Lineage Cell Therapeutics Secures $14M in Direct Offering

See More Headlines

Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:LCTX
CUSIP: N/A
CIK: N/A
Web: www.lineagecell.com
Phone: (442) 287-8963
Fax: 510-521-3389
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.50
High Stock Price Target: $7.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +403.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,490,000.00
Net Margins: -240.20%
Pretax Margin: -260.28%
Return on Equity: -31.95%
Return on Assets: -19.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.14
Quick Ratio: 2.14

Sales & Book Value

Annual Sales: $8.94 million
Price / Sales: 27.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 3.69

Miscellaneous

Outstanding Shares: 188,530,000
Free Float: 135,556,000
Market Cap: $243.20 million
Optionable: Not Optionable
Beta: 1.31

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Brian M. Culley M.A. (Age 53)
M.B.A., CEO, President & Director
Comp: $944.15k
Ms. Jill Ann Howe (Age 47)
CFO & Principal Financial and Accounting Officer
Comp: $125.52k
Mr. George A. Samuel III (Age 43)
J.D., General Counsel & Company Secretary
Comp: $560.95k
Ioana C. Hone
Director of Investor Relations
Ms. Brandi L. Roberts CPA (Age 50)
M.B.A., Consultant
Comp: $407.45k
Mr. William Annett MBA (Age 70)
President & CEO of OncoCyte Corporation
Comp: $53.2k
Dr. Rami Skaliter Ph.D. (Age 66)
Chief Executive Officer of Cell Cure Neurosciences
Ms. Alexandra Hernandez
Senior Director of Finance & Controller
Dr. Harold D. Waitz (Age 82)
Vice President of Regulatory Affairs & Quality Control
Comp: $90k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LCTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Lineage Cell Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lineage Cell Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LCTX shares.
View LCTX analyst ratings or view top-rated stocks.
What is Lineage Cell Therapeutics' stock price target for 2024?: 2 Wall Street research analysts have issued 1-year price objectives for Lineage Cell Therapeutics' shares. Their LCTX share price targets range from $6.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 403.9% from the stock's current price.
View analysts price targets for LCTX or view top-rated stocks among Wall Street analysts.
When is Lineage Cell Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our LCTX earnings forecast.
How were Lineage Cell Therapeutics' earnings last quarter?: Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04. The company earned $2.09 million during the quarter, compared to analyst estimates of $4.74 million. Lineage Cell Therapeutics had a negative net margin of 240.20% and a negative trailing twelve-month return on equity of 31.95%.

What other stocks do shareholders of Lineage Cell Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lineage Cell Therapeutics investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Enerplus (ERF), KushCo (KSHB) and Zosano Pharma (ZSAN).
Who are Lineage Cell Therapeutics' major shareholders?: Lineage Cell Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fifth Third Wealth Advisors LLC (0.01%). Insiders that own company stock include Angus C Russell, Brian M Culley, Broadwood Partners, LP, Dipti Amin, Don M Bailey, Gary S Hogge and Michael H Mulroy.
View institutional ownership trends.
How do I buy shares of Lineage Cell Therapeutics?: Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:LCTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Lineage Cell Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)

LCTX Stock Price History

LCTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LCTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™